Pharma Focus Asia

CHO Plus Announces Research Collaboration Agreement With Janssen

Wednesday, December 02, 2020

CHO Plus (, an early-stage innovation company developing technology to vastly increase the productivity of cells used to manufacture therapeutic proteins, announced today that it has entered into a research collaboration agreement with Janssen Biotech, Inc. (Janssen), one of the Pharmaceutical Companies of Johnson & Johnson. This agreement will allow CHO Plus to demonstrate commercial feasibility of its technology, while also developing several custom projects for Janssen. Under the agreement terms, Janssen will have the non-exclusive right to license CHO Plus technology for production of its therapeutic proteins. The agreement was facilitated by Johnson & Johnson Innovation.

“We are pleased to have entered into this collaboration with Janssen as we advance our technology for use in GMP production of licensed therapeutic proteins,” said Larry Forman, CHO Plus Co-founder and CEO.

Larry Chasin, CHO Plus Co-founder and Chief Scientific Advisor, commented: “It’s great to see this unique technology making its way into the commercial sector, where the expected productivity benefits can quickly be realized.”

CHO Plus laboratories are currently located at the Johnson & Johnson Innovation – JLABS incubator in South San Francisco, CA.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024